Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

17:54
10/09/16
10/09
17:54
10/09/16
17:54

Bristol-Myers reports data from CheckMate-057, CheckMate-017 trials

Bristol-Myers Squibb announced updated results from two pivotal Phase 3 studies, CheckMate -057 and CheckMate -017, which showed more than one-third of previously treated metastatic non-small cell lung cancer patients in both trials experienced ongoing responses with Opdivo, compared to no ongoing responses in the docetaxel arm. The median duration of response with Opdivo versus docetaxel in CheckMate -057 was 17.2 months and 5.6 months, respectively, and in CheckMate -017 it was 25.2 months and 8.4 months, respectively. In CheckMate -057, patients with PD-L1 greater than or equal to 1% had a median DOR of 17.2 months and in patients with PD-L1 less than 1%, it was 18.3 months. In both studies, durability of response was observed in both PD-L1 expressors and non-expressors, and in CheckMate -057, one out of the four complete responses occurred in a patient with less than 1% PD-L1 expression. There were no new safety signals identified for Opdivo in the pooled safety analysis from both studies. No new treatment-related deaths occurred between one and two years' minimum follow-up despite the longer treatment exposure, and new events were observed in 11/418 patients with an additional one year of follow up. Patient-reported outcomes from CheckMate -057 were also presented. Findings show Opdivo provided better preservation of health status, health-related quality of life and symptom control versus docetaxel, as assessed by the EuroQoL-5 Dimensions, visual analog scale, and the Lung Cancer Symptom Score.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

, SPX

S&P 500

14:13
09/20/17
09/20
14:13
09/20/17
14:13
Technical Analysis
Technical View: S&P 500 slips below the pivot low »

The S&P 500 (SPX) is…

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZRX

PhaseRx

$0.78

0.055 (7.64%)

14:11
09/20/17
09/20
14:11
09/20/17
14:11
Hot Stocks
PhaseRx confirms receipt of FDA orphan drug designation for PRX-ASL »

PhaseRx announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$49.34

0.24 (0.49%)

14:10
09/20/17
09/20
14:10
09/20/17
14:10
Hot Stocks
Sanofi reports 'potential breakthrough' in preclinical work on HIV antibodies »

Researchers working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SPX

S&P 500

14:06
09/20/17
09/20
14:06
09/20/17
14:06
General news
Fed details plans to being reducing balance sheet »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$14.06

0.29 (2.11%)

14:05
09/20/17
09/20
14:05
09/20/17
14:05
Options
Valeant call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

, SPX

S&P 500

14:04
09/20/17
09/20
14:04
09/20/17
14:04
General news
Federal Reserve maintains median projection for year-end funds rate at 1.4% »

The Fed's "dot…

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:02
09/20/17
09/20
14:02
09/20/17
14:02
General news
Fed says economic activity rising moderately this year »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$68.25

-0.24 (-0.35%)

, SYMC

Symantec

$34.16

0.39 (1.15%)

14:02
09/20/17
09/20
14:02
09/20/17
14:02
Periodicals
Breaking Periodicals news story on Splunk, Symantec »

Symantec 'play'…

SPLK

Splunk

$68.25

-0.24 (-0.35%)

SYMC

Symantec

$34.16

0.39 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SPX

S&P 500

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
Fed plans to initiate balance sheet normalization in October »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
FOMC Meeting Announcement Federal Funds Rate data reported »

FOMC Meeting Announcement…

14:00
09/20/17
09/20
14:00
09/20/17
14:00
General news
Breaking General news story  »

Federal Reserve leaves…

RNVA

Rennova Health

$0.22

-0.0021 (-0.93%)

13:55
09/20/17
09/20
13:55
09/20/17
13:55
Conference/Events
Rennova Health to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MLCO

Melco Resorts & Entertainment

$23.78

0.77 (3.35%)

13:50
09/20/17
09/20
13:50
09/20/17
13:50
Options
Bullish option play opened in Melco Resorts as shares tick to 52-week highs »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

, UNH

UnitedHealth

$195.34

0.69 (0.35%)

13:48
09/20/17
09/20
13:48
09/20/17
13:48
Periodicals
McConnell intends to consider healthcare bill in Senate next week, WSJ says »

A spokesman for Senate…

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

UNH

UnitedHealth

$195.34

0.69 (0.35%)

CNC

Centene

$90.10

0.32 (0.36%)

WCG

WellCare

$166.10

-2.065 (-1.23%)

CI

Cigna

$181.44

-0.07 (-0.04%)

ANTM

Anthem

$181.90

0.46 (0.25%)

HNT

Health Net

HUM

Humana

$238.58

-1.46 (-0.61%)

AET

Aetna

$154.56

-1.48 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

JCI

Johnson Controls

$40.12

1.075 (2.75%)

13:45
09/20/17
09/20
13:45
09/20/17
13:45
Options
Johnson Controls call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
09/20/17
09/20
13:45
09/20/17
13:45
General news
Breaking General news story  »

FOMC Forecasts to be…

13:45
09/20/17
09/20
13:45
09/20/17
13:45
General news
FOMC Meeting Announcement Federal Funds Rate to be reported at 14:00 »

FOMC Meeting Announcement…

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

13:35
09/20/17
09/20
13:35
09/20/17
13:35
Hot Stocks
Breaking Hot Stocks news story on JAKKS Pacific »

JAKKS Pacific expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
09/20/17
09/20
13:35
09/20/17
13:35
General news
NY Fed accepted $168.03 B in daily reverse repos »

NY Fed accepted $168.03 B…

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

13:33
09/20/17
09/20
13:33
09/20/17
13:33
Hot Stocks
JAKKS Pacific expects to sustain net loss, negative EPS for the year »

JAKKS still expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$34.95

0.1 (0.29%)

13:33
09/20/17
09/20
13:33
09/20/17
13:33
Earnings
Notable companies reporting after market close »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

13:32
09/20/17
09/20
13:32
09/20/17
13:32
Hot Stocks
JAKKS Pacific doesn't see LT material adverse impact from Toys 'R' Us filing »

JAKKS Pacific announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

13:30
09/20/17
09/20
13:30
09/20/17
13:30
Options
Flurry of activity in Blackberry as shares rally »

Flurry of activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATVI

Activision Blizzard

$64.31

0.11 (0.17%)

13:29
09/20/17
09/20
13:29
09/20/17
13:29
Recommendations
Activision Blizzard analyst commentary  »

Activision launch of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWN

Southwestern Energy

$6.07

0.09 (1.51%)

13:25
09/20/17
09/20
13:25
09/20/17
13:25
Options
Southwestern Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.